Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N15/50

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2023/001259PREPARATION AND APPLICATION OF RECOMBINANT MULTIVALENT NOVEL CORONAVIRUS TRIMER PROTEIN VACCINE CAPABLE OF INDUCING BROAD-SPECTRUM AND NEUTRALIZING ACTIVITY
WO 26.01.2023
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/CN2022/107213 Applicant SINOCELLTECH LTD Inventor XIE, Liangzhi
A recombinant multivalent novel coronavirus trimer protein vaccine capable of inducing broad-spectrum and neutralizing activity. The recombinant protein component comprises, but is not limited to, a homotrimer protein formed by introducing, into an extracellular domain (ECD) of B.1.617.1 strain and B.1.617.2 strain spike (S) proteins, a mutation site and a trimerization assistance structure. The multivalent vaccine comprises an ECD trimer protein of a single component or any combination of components of the variant strains above, and a pharmaceutically acceptable adjuvant. The vaccine combination shows excellent immunogenicity in mice, and can maintain long-term humoral immunity and cellular immunity. The multivalent novel coronavirus trimer protein vaccine can be used for preventing infection-related diseases caused by infection of novel coronavirus and variant strains thereof.
2.102021013930DIAGNÓSTICO IMUNOLÓGICO DA COVID-19
BR 24.01.2023
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No 102021013930 Applicant UNIVERSIDADE FEDERAL DE PELOTAS Inventor ANA VITÓRIA COSTA
DIAGNÓSTICO IMUNOLÓGICO DA COVID-19. A presente invenção enquadra-se na área de Biotecnologia e refere-se a um ensaio imunoabsorvente (ELISA) que detecta e mensura anticorpos IgG, IgM ou IgA anti-SARSCov-2, agente etiológico da COVID-19, para fins de diagnóstico clínico, estudos epidemiológicos, monitoramento vacinal e pesquisa/desenvolvimento tecnológico. Diferentemente da maioria dos testes sorológicos comerciais que utiliza uma proteína de SARS-Cov-2 como antígeno (S ou N), a presente invenção descreve a produção e uso em imunodiagnóstico de uma quimera recombinante composta por regiões imunodominantes das duas principais proteínas antigênicas de SARS-Cov-2, conferindo elevada sensibilidade e especificidade ao teste. Esta quimera antigênica é produzida em alta quantidade por Escherichia coli e apresenta elevada estabilidade. A otimização de todas as etapas e insumos usados no ELISA com um painel de 1000 soros nacionais possibilitou o desenvolvimento de um teste de elevada acurácia e reprodutibilidade.
3.WO/2023/287324INFLUENZA VIRUS-BASED ISOLATED RECOMBINANT VIRUS
WO 19.01.2023
Int.Class C12N 15/117
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
Appl.No PCT/RU2022/050173 Applicant JOINT STOCK COMPANY "BIOCAD" Inventor RUDENKO, Larisa Georgievna
The present invention relates to the fields of biotechnology, immunology, virology, genetics, and molecular biology. More specifically, the present invention relates to an isolated nucleic acid encoding a recombinant polypeptide for increasing the titer of antibodies to influenza virus (variants), an influenza virus-based recombinant virus for inducing specific immunity to influenza virus and/or preventing influenza virus-related diseases, a pharmaceutical composition and a vaccine that include the above influenza virus-based recombinant virus, as well as their use for inducing specific immunity to influenza virus and/or preventing influenza virus-related diseases.
4.2021121139Выделенный рекомбинантный вирус на основе вируса гриппа для индукции специфического иммунитета к вирусу гриппа и/или профилактики заболеваний, вызванных вирусом гриппа
RU 16.01.2023
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 2021121139 Applicant Акционерное общество "БИОКАД" (RU) Inventor Руденко Лариса Георгиевна (RU)
5.WO/2023/280220S PROTEIN VARIANT OF CORONAVIRUS AND USE THEREOF
WO 12.01.2023
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/CN2022/104158 Applicant FUDAN UNIVERSITY Inventor LIN, Jinzhong
The present invention relates to an S protein variant, which does not contain a complete cytoplasmic tail domain compared to an S protein of a wild-type coronavirus. Further provided are a nucleic acid molecule encoding the S protein variant, and the use of the S protein variant and the nucleic acid molecule in the preparation of a vaccine.
6.2023500928ベクターとしてのアレナウイルス
JP 11.01.2023
Int.Class A61P 31/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
Appl.No 2022526205 Applicant ユニベルシタト バーゼル Inventor ダニエル ピンスチェワー
本出願は、アレナウイルスオープンリーディングフレーム(「ORF」)が2以上の機能性断片中に隔離され、これらの断片が2以上のウイルスmRNA転写物から発現されるように改変されたゲノムを含有するアレナウイルス粒子に関する。本明細書に記載されるアレナウイルス粒子は、遺伝的に安定であり、かつ高レベルの導入遺伝子発現を提供する。ある実施態様において、該アレナウイルス粒子は3セグメント化されている。特に、本明細書に記載されるのは、アレナウイルスGP、NP、L、又はZの機能性断片をコードするヌクレオチド配列を含む1以上のORFを含むヌクレオチド配列である。また本明細書に記載されるのは、アレナウイルスORFが2以上の機能性断片中に隔離され、これらの断片が2以上のウイルスmRNA転写物から発現されるように改変されたゲノムを含有するアレナウイルス粒子である。また本明細書に記載されるのは、その転写が、アレナウイルスGP、NP、L、又はZの機能性断片をコードするヌクレオチド配列を含む1以上のmRNA転写物を生じさせるように改変されたアレナウイルスゲノム又はアンチゲノムセグメントである。本明細書に記載されるアレナウイルス粒子は、ワクチン及び/もしくは疾患の治療のために並びに/又は免疫療法における使用のために好適であり得る。
【選択図】図4C
7.2023003315コロナウイルスワクチン
JP 11.01.2023
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 2021104415 Applicant 国立感染症研究所長 Inventor 石井 洋
【課題】本発明はコロナワクチン、その製造方法、およびその使用を提供することを課題とする。
【解決手段】本発明は、コロナウイルスの非スパイク蛋白質を標的抗原とするワクチン組成物であって、該標的抗原蛋白質に対するT細胞応答を誘導するワクチン組成物その製造方法、およびその使用を提供する。本発明のワクチンは、スパイク抗原非依存的にコロナウイルスに対する防御効果を発揮し、中和抗体に必ずしも依存せず、T細胞応答、特にCD8+ T細胞応答の誘導を介してその効果を発揮する。スパイク抗原に対する中和抗体を誘導するワクチンは、スパイク蛋白質の変異体の出現による効果の低下が懸念されるが、本発明のワクチンはその問題を克服する新たなワクチンとして有用である。
【選択図】なし
8.115584352猪流行性腹泻病毒(PEDV)ORF3和E蛋白反式互补单轮感染系统及应用
CN 10.01.2023
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No 202110763876.1 Applicant 复旦大学 Inventor 张荣
本发明属于生物医药技术领域,涉及猪流行性腹泻病毒(PEDV)ORF3和E蛋白反式互补单轮感染系统及应用,本发明以临床分离的PEDV GII型毒株HN20的全基因组序列为基础,将PEDV全基因组序列分为A、B、C、D和E共5个片段,分别插入载体pSMART中,同时将A片段中的SapI内切酶酶切位点和E片段中的BsmBI内切酶酶切位点进行同义突变作为分子标记并删除E片段中的ORF3和E基因编码框。将构建的5个重组质粒分别进行酶切,胶回收,体外连接转录后,将转录的RNA电转进诱导表达PEDV ORF3和E蛋白的BHK‑21细胞中,拯救出单轮感染的PEDV病毒。本发明的PEDV ORF3和E蛋白的反式互补单轮感染系统有助于PEDV的抗病毒药物、致病机制以及新型疫苗的研制。
9.115572714一种快速检测SARS-CoV-2病毒中和抗体有效性的方法
CN 06.01.2023
Int.Class C12N 5/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
Appl.No 202110684183.3 Applicant 江苏泽凯生物医药技术有限公司 Inventor 王洁
本发明公开了一种稳定表达SARS‑CoV‑2病毒结构蛋白M、N、E的细胞株,将SARS‑CoV‑2‑S质粒和Ha‑CoV‑2‑Luc质粒共转染可以生产SARS‑CoV‑2病毒样颗粒,进一步用于SARS‑CoV‑2病毒中和抗体有效性检测。使用本发明构建的稳定表达SARS‑CoV‑2蛋白(M、N、E)的细胞株,可快速有效产出大量具有全部SARS‑CoV‑2结构蛋白(M、N、E、S)的病毒样颗粒。该病毒样颗粒不仅与SARS‑CoV‑2更为相似,而且安全性可控,具有荧光表达基因,可在几个小时内实现准确快速的SARS‑CoV‑2中和抗体有效性检测,对有效应对SARS‑CoV‑2病毒具有重要意义。
10.115572736猪流行性腹泻病毒(PEDV)N蛋白反式互补单轮感染系统的构建及应用
CN 06.01.2023
Int.Class C12N 15/867
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
867Retroviral vectors
Appl.No 202110762447.2 Applicant 复旦大学 Inventor 张荣
本发明属于生物医药技术领域,涉及猪流行性腹泻病毒(PEDV)N蛋白反式互补单轮感染系统及应用。本发明以临床分离的PEDV GII型毒株HN20的全基因组序列为基础,将PEDV全基因组序列分为A、B、C、D和E共5个片段,分别插入载体pSMART中,同时将A片段中的SapI内切酶酶切位点和E片段中的BsmBI内切酶酶切位点进行同义突变作为分子标记并删除E片段中的N基因编码框;将构建的5个重组质粒分别进行酶切,胶回收,体外连接转录后,将转录的RNA电转进稳定表达PEDV N蛋白的BHK‑21细胞中,拯救出单轮感染的PEDV病毒。本发明的PEDV N蛋白反式互补单轮感染系统,有助于PEDV的抗病毒药物、致病机制以及新型疫苗的研制。